Red Ridge Bio
Building therapies for oncology and autoimmunity
- Headquarters
- Basel
- Employees
- 1–10
- Business Model
- B2B
- Website
- redridgebio.com
- Last Round
- Series AApr 2025
- Rounds
- 1
About
RedRidge Bio is a clinical-stage biotech company specializing in the discovery and development of biparatopic antibodies (BPAs) — antibodies that simultaneously target two distinct epitopes on a single protein — for cancer and autoimmune diseases. The company's lead assets include biparatopic antibody-drug conjugates for liquid and solid tumors, as well as tissue-tethered immune cell modulators for inflammatory diseases. RedRidge Bio combines high-throughput screening, structural biology, and disease biology expertise to engineer best-in-class therapeutics with superior efficacy and long-term safety profiles.
Summary
Red Ridge Bio is a Biotech company based in Basel, Switzerland. Its most recent funding was a Series A round in Apr 2025. Investors include New Enterprise Associates.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Apr 2025
Investors
Similar Companies
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...
Biopharmaceutical company pioneering Helicon peptide drugs to target previously undruggable prote...
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...